

1 **HOUSE OF REPRESENTATIVES - FLOOR VERSION**

2 STATE OF OKLAHOMA

3 2nd Session of the 55th Legislature (2016)

4 COMMITTEE SUBSTITUTE
5 FOR ENGROSSED
6 SENATE BILL NO. 127

By: David of the Senate

and

Newell of the House

8
9
10 COMMITTEE SUBSTITUTE

11 [Oklahoma Health Care Authority - fee schedule -
12 reimbursement and utilization rates - testing -
13 preauthorization requirements - effective date]

14
15
16 BE IT ENACTED BY THE PEOPLE OF THE STATE OF OKLAHOMA:

17 SECTION 1. NEW LAW A new section of law to be codified
18 in the Oklahoma Statutes as Section 5030.6 of Title 63, unless there
19 is created a duplication in numbering, reads as follows:

20 A. The Oklahoma Health Care Authority shall utilize the
21 Clinical Laboratory Fee Schedule published by the Centers for
22 Medicare and Medicaid Services and associated frequency guidelines
23 when determining reimbursement and utilization rates for definitive
24 drug testing; provided, the total amount reimbursed for such

1 screenings in any fiscal year shall not exceed the amount reimbursed
2 by the Authority in fiscal year 2012. Referring clinicians are
3 required to document medical necessity and risk status of every
4 patient receiving definitive testing.

5 B. The Authority is authorized to establish preauthorization
6 requirements for testing only for high risk frequency patients as
7 defined by the guidelines of the CMS.

8 SECTION 2. This act shall become effective November 1, 2016.

9
10 COMMITTEE REPORT BY: COMMITTEE ON APPROPRIATIONS AND BUDGET, dated
11 04/07/2016 - DO PASS, As Amended.
12
13
14
15
16
17
18
19
20
21
22
23
24